A fast and low risk approach to drug development

WHY INVEST IN SISAF?

New drug discovery is very costly, time consuming and risky. Only one in ten new drugs make it to market and it’s estimated to cost over $2.5 billion per drug. SiSaf pursues a much faster and lower risk approach to drug development.

We take existing tried and tested active pharmaceutical ingredients and reformulate them with ProSilic®. When our formulation has passed ‘proof of concept’, the risk of clinical failure is lowered and the timeline to market in the U.S. is shortened. Typically, it takes just three years via the 505(b)2 regulatory pathway.

We have set up a specialist subsidiary for cosmetic skincare, a high-value, low barrier to entry market.

INVESTMENT CASE

$170 Bn addressable market opportunity

Unique, proven and scalable technology. Granted patent protection until 2032

Experienced leadership team with a strong track record. A clear strategy and manufacturing capacity to rapidly exploit platform technology potential

Drug reformulation instead of drug discovery means faster route to market and lower risk.

Revenue from strategic partnership, license deals and product sales

OUR INVESTORS